Active Ingredient(s): Ozanimod Hydrochloride
FDA Approved: * March 25, 2020
Pharm Company: * CELGENE INTL
Category: Multiple Sclerosis

Ozanimod, sold under the brand name Zeposia, is an immunomodulatory medication for the treatment of relapsing multiple sclerosis and ulcerative colitis.[2][3][4][5] It acts as a sphingosine-1-phosphate (S1P) receptor agonist, sequestering lymphocytes to peripheral lymphoid organs and away from their sites of chronic inflammation.[4] The most common adverse reactions are upper respiratory infection, hepatic transam... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Zeposia .92 mg Oral Capsule
NDC: 59572-820
Celgene Corporation